Galectin-3 Inhibitor Compounds for Fibrosis and Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases and disorders related to galectin-3 binding to natural ligands are inadequate, as galectin-3 is involved in various pathological processes including inflammatory, autoimmune, and fibrotic diseases, and there is a need for effective galectin-3 inhibitors.
Innovation Solution
Development of novel compounds of formula (I) that act as galectin-3 inhibitors, which can be used alone or in combination with other therapeutic agents for the prevention or treatment of diseases related to galectin-3 binding.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for diseases related to galectin-3 binding, then existing therapeutic approaches are maintained, but treatment effectiveness is inadequate
Solution Approach 1:
The patent employs parameter changes by developing compounds with specific molecular structures (formula I) that optimize binding affinity to galectin-3. By varying structural parameters such as the aryl group (Ar1), heteroaryl group (Ar2), linker (L), and substituent positions, the invention achieves enhanced treatment effectiveness across multiple disease types including fibrotic, inflammatory, and cardiovascular diseases
Solution Approach 2:
The patent applies universality by creating a single compound class (galectin-3 inhibitors of formula I) that can treat multiple different diseases and disorders. The compounds demonstrate broad therapeutic applicability across fibrotic diseases, inflammatory diseases, autoimmune diseases, cardiovascular diseases, kidney diseases, and cancer, making one solution serve multiple therapeutic functions
2Adaptability or versatility
If galectin-3 inhibitors are developed to treat multiple diseases, then therapeutic versatility is improved, but compound complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the galectin-3 inhibitor compound into distinct functional modules: an aryl group (Ar1), a heteroaryl group (Ar2), a linker (L), and various substituent groups. This modular structure allows systematic optimization of each component's contribution to binding affinity while maintaining overall manageability of the complex molecule
Solution Approach 2:
The patent implements local quality by assigning specific functional roles to different parts of the molecule. The aryl group (Ar1) and heteroaryl group (Ar2) are designed with specific substituents (halogen, alkyl, alkoxy, amino groups) at particular positions to optimize local interactions with galectin-3 binding sites, while the linker (L) provides flexible connection. This localized optimization enables the complex compound to achieve high versatility across multiple diseases without requiring complete redesign for each application
Data Source
AI summary
The present invention relates to compounds of Formula (I)wherein Ar1, Ar2, L, n, and R1 are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of Formula (I), and especially to their use as Galectin-3 inhibitors.